NCT07660848RecruitingPhase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Master Protocol Clinical Trial to Investigate the Efficacy and Safety of HRS-4729 Injection and HRS9531 Injection in Adult Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Fujian Shengdi Pharmaceutical Co., Ltd.2 sites in 1 country160 target enrollmentStarted: August 14, 2026Last updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 160
- Locations
- 2
Study Overview
Brief Summary
The purpose of this study is to investigate the efficacy and safety of HRS-4729 injection and HRS9531 injection in adult participants with metabolic dysfunction-associated steatohepatitis after 52 weeks of treatment.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Able and willing to provide a written informed consent
- •Participants must have histologic diagnosis of MASH by liver biopsy
- •Have liver fat content ≥8%
- •Participants must have a body mass index (BMI) ≥24 kilograms per square meter (kg/m²) and ≤40 kg/m² with stable body weight for at least 3 months
Exclusion Criteria
- •Model for End-Stage Liver Disease (MELD) score > 12, or Child-Pugh (CTP) score > 6
- •Known or suspected history of excessive alcohol consumption or alcohol dependence within 12 months prior to screening
- •History of liver cirrhosis and/or liver decompensation, including but not limited to ascites, hepatic encephalopathy, esophageal or gastric variceal bleeding, etc.
- •Previous or current liver disease due to other causes, including but not limited to: alcoholic steatohepatitis (ASH), drug-induced liver injury (DILI), viral hepatitis, autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), hereditary hepatobiliary diseases (e.g., hemochromatosis, α1-antitrypsin deficiency, Wilson's disease, etc.), occupational toxic liver disease, known or suspected hepatocellular carcinoma (HCC), etc.
- •History of or planned organ transplantation (e.g., liver transplant) or bone marrow transplantation during the study period
- •Use of GLP-1 receptor agonists (including multi-target drugs or compound preparations containing GLP-1 receptor agonists) within 3 months prior to screening, or previous discontinuation of GLP-1 receptor agonists due to safety/tolerance reasons
- •Known or suspected hypersensitivity to GLP-1 and/or GIP and/or GCG receptor agonists and/or their excipient
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Phase 2
A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes MellitusT2DMNCT07599410Fujian Shengdi Pharmaceutical Co., Ltd.240
Active, not recruiting
Phase 2
Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute PancreatitisNCT07308392Fujian Shengdi Pharmaceutical Co., Ltd.119
Recruiting
Phase 1
A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee OsteoarthritisNCT07351968Shandong Suncadia Medicine Co., Ltd.200
Recruiting
Phase 3
Phase III Study of HRS-7535 for Hypertension With Overweight or ObesityHypertension With Overweight or ObesityNCT07528027Shandong Suncadia Medicine Co., Ltd.648
Recruiting
Phase 2
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous NephropathyNCT07289763Guangdong Hengrui Pharmaceutical Co., Ltd75